Read the Phase 1 Study: Intravenous VCN-01 Oncolytic Adenovirus + Durvalumab for HNMSCC Refractory to Immunotherapy (NCT03799744), in Clinical Cancer Research. buff.ly/TYAy9S1
AACR Journals
@aacrjournals.bsky.social
The American Association for Cancer Research’s 10 peer-reviewed journals provide a renowned, respected forum for publishing the most innovative cancer science, encompassing the full spectrum of basic, translational, clinical, and epidemiological research.
The Cancer Epidemiology, Biomarkers & Prevention Reviewer Training Program provides a unique opportunity to gain peer reviewer experience and to become more effective at scientific peer review. Learn more: buff.ly/VZdrxTw #PeerReviewWeek #PRW2026
Read the Phase 2 Study: TQB2618 + Penpulimab for Recurrent or Metastatic Nasopharyngeal Carcinoma (NCT05563480), in Clinical Cancer Research. buff.ly/bV9p76c
Dr. Manel Esteller, recipient of the Cancer Research Communications Award for Outstanding Journal Article, discusses how single-cell multiomics might change the way we interpret clinical responses and resistance in MDS. Watch the interview: buff.ly/kvs5CQt @manelesteller.bsky.social
In the clip below, Tomasz M. Beer, MD, recipient of the 2026 Cancer Prevention Research Award for Outstanding Journal Article, discusses what he sees as some of the most important insights from his study. To learn more, watch the full interview: buff.ly/R9dQCUp
Through the Guaranteed Peer Review program, Active Members of AACR who peer review at least three manuscripts for one or more AACR journals can qualify to request that their own submitted manuscript be automatically sent for external peer review. #PeerReviewWeek #PRW2026 Learn more: buff.ly/Nb8y5Ce
In Clinical Cancer Research, read the phase 2 Study: Trifluridine/Tipiracil in Recurrent/Metastatic Platinum Resistant Nasopharyngeal Carcinomas (NCT04627961). buff.ly/rCRGyU7
Read about recent advances in fundamental and clinical research on myeloid neoplasms published in Blood Cancer Discovery, in the Myeloid Neoplasms collection: buff.ly/HrAs2a0
From the September issue of Molecular Cancer Research: Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer ➡️Read the Cancer Research Resources article: buff.ly/SUNnKpT
Read the recent Cancer Immunology Research article featured by ACIR: KRAS-G12C inhibition-induced enrichment of MHC-Ihigh immune-active tumor cells directs immune-effector TME development to augment therapeutic efficacy doi.org/10.1158/2326...
KRAS-G12C inhibition-induced enrichment of MHC-Ihigh immune-active tumor cells directs immune-effector TME development to augment therapeutic efficacy
Abstract. Inhibition of KRASG12C (G12Ci) has shown promising clinical activity in several cancers; however, emergence of resistance is a major limitation to long-term benefit. It remains unknown how G...
doi.org
ACIR@acir-org.bsky.social · 3d agoFine-tuning IL-2 delivery for cancer immunotherapy acir.org/weekly-dige...
Groeneveldt et al. investigated mechanisms driving early-stage immune-related adverse events (irAEs) in patients with metastatic melanoma treated with combination ICB (anti-PD-1 and anti-CTLA-4). bit.ly/4A4rx8O @aacrjournals.bsky.social
Read the Phase 1 Study: [68Ga]Ga/[177Lu]Lu-JH120061, A Novel Radiopharmaceutical Targeting CXCR4 (NCT06688188), in Clinical Cancer Research. buff.ly/7oXZBY4
"Editors and staff are fantastic to interact with. It is always easy to reach out, get feedback and suggestions." -Sandra Misale, Cancer Discovery Author See more of what our authors are saying about publishing with the Journals. buff.ly/7x8ra8e
Read: "Tumor-Infiltrating Clonal Hematopoiesis Is Associated with Adverse Clinical Outcomes in Diffuse Large B-cell Lymphoma" from this month's issue of Blood Cancer Discovery. buff.ly/WxQ1713
Read: "Germline noncoding risk variants influence clonal hematopoiesis through altered hematopoietic enhancer activity," by Satish Nandakumar, et al. buff.ly/NwzCsLa This article was recently presented by co-author Keisuke Ito at #ISEH2026. @nandakumarlab.bsky.social
Cancer Research Communications is committed to providing rigorous peer review by a team of editors who are leaders in the field. Learn more about how @theaacr.bsky.social's #OpenAccess journal supports authors from presubmission through publication: buff.ly/QbODtSF
Read the Phase 1 Study: Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Advanced Solid Tumors (NCT04939610), in Clinical Cancer Research. buff.ly/CKaX88p
Molecular Cancer Therapeutics highlights novel cancer therapies through its #FirstDisclosure article type. These articles present drugs for the first time in published literature. Check out recently published First Disclosures: buff.ly/FleTsdi
Read: "Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR T–Treated T-cell Lymphoid Malignancies " from this month's issue of Blood Cancer Discovery. buff.ly/z8KU8cn
Phase 2 Study: Genomics of EGFRm NSCLC after First-line Osimertinib (NCT03944772), in Clinical Cancer Research. buff.ly/aZm19uu
Read the Phase 2 Study: Neratinib Alone or with Trastuzumab in HER2-Mutant TNBC (NCT01953926), in Clinical Cancer Research. buff.ly/Ruwm1yB
Hear from authors and learn about how the power of simultaneous publication can amplify your research impact by broadly disseminating your work to thousands of attendees and readers. To learn more about how the AACR Journals will amplify your research impact, visit buff.ly/xFawu3Z
Read the Hot Topics article collections, featuring impactful, cutting-edge research published in the AACR Journals: buff.ly/l0WH2jW #WCLC26
In Clinical Cancer Research: Rethinking Molecular Profiling after First-line Osimertinib. buff.ly/Yv9oToD
Read the new Clinical Hemato-Oncology article collection showcasing Blood Cancer Discovery content on clinical hemato-oncology research and practice, encompassing biology-informed prognostication, new therapies, clinical trials, and post-approval real-life outcomes. buff.ly/LqRwkla #SOHO2026
The AACR Journals offers the Guaranteed Peer Review program. Members who peer review at least three manuscripts for one or more AACR journals can qualify to have their own submitted manuscript be automatically sent for external peer review. ➡️Learn more: buff.ly/mivP542
Visit @theaacr.bsky.social Booth 113 at #WCLC26 and pick up the AACR Journals brochure to read the latest groundbreaking research published in the Journals.
Read the Cancer Research Resources article: Archetype Analysis of Lung Adenocarcinoma Premalignancy Links Heterogeneity in Premalignant Lesions to Diverging Features of Invasive Disease, in Molecular Cancer Research buff.ly/XX2TiAy
